Our pipeline encompasses T cell therapies targeting well-studied cancer specific antigens, e.g. testis antigens, mutated oncogenes, viral antigens. Our lead program for liver cancer, ET1402, is expected to enter Phase I in 2017.
Collaborations are a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.